Apical dose versus volume dose of Ruthenium-106 brachytherapy for uveal melanoma.

Journal

Canadian journal of ophthalmology. Journal canadien d'ophtalmologie
ISSN: 1715-3360
Titre abrégé: Can J Ophthalmol
Pays: England
ID NLM: 0045312

Informations de publication

Date de publication:
03 Apr 2024
Historique:
received: 01 12 2023
revised: 09 02 2024
accepted: 12 03 2024
medline: 7 4 2024
pubmed: 7 4 2024
entrez: 6 4 2024
Statut: aheadofprint

Résumé

Ruthenium-106 brachytherapy is commonly used to treat uveal melanomas. Most centres prescribe a radiation dose to the tumour apex that is calculated with the tumour located in the centre of the plaque. Recent work suggests that D The time required to deliver 100 Gy to the tumour apices of representative tumours ranging from 2- to 6-mm thickness with central plaque positioning was calculated in Plaque Simulator™. This treatment time was used for further calculations, including D D D

Identifiants

DOI: 10.1016/j.jcjo.2024.03.007 PMID: 38582499
pubmed: 38582499
pii: S0008-4182(24)00074-7
doi: 10.1016/j.jcjo.2024.03.007
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Footnotes and Disclosure Funding: This research did not receive any specific grant from funding agencies in the public, commercial or not-for-profit sectors Commercial relationships disclosures: Emeritus Professor M.A. Astrahan is the proprietary founder and owner of the Plaque Simulator(TM) software. Nil additional disclosures by any other author.

Auteurs

Jeremy P M Flanagan (JPM)

Ophthalmology, Department of Surgery, University of Melbourne, Melbourne (Victoria), Australia; Ocular Oncology Research Unit, Centre for Eye Research Australia, Melbourne (Victoria), Australia.

Lotte S Fog (LS)

Department of Ocular Oncology, Royal Victorian Eye and Ear Hospital, Melbourne (Victoria), Australia.

Melvin A Astrahan (MA)

Department of Radiation Oncology, Keck School of Medicine, University of Southern California, Los Angeles, California.

Lachie J Talbot (LJ)

Ophthalmology, Department of Surgery, University of Melbourne, Melbourne (Victoria), Australia.

Daniel McKay (D)

Ocular Oncology Research Unit, Centre for Eye Research Australia, Melbourne (Victoria), Australia; Department of Ocular Oncology, Royal Victorian Eye and Ear Hospital, Melbourne (Victoria), Australia.

Claire Phillips (C)

Department of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne (Victoria), Australia.

John D McKenzie (JD)

Department of Ocular Oncology, Royal Victorian Eye and Ear Hospital, Melbourne (Victoria), Australia.

Roderick O'Day (R)

Ocular Oncology Research Unit, Centre for Eye Research Australia, Melbourne (Victoria), Australia; Department of Ocular Oncology, Royal Victorian Eye and Ear Hospital, Melbourne (Victoria), Australia. Electronic address: roderick.o'day@eyeandear.org.au.

Classifications MeSH